TY - JOUR
T1 - Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension
AU - Di Trani, Nicola
AU - Liu, Hsuan Chen
AU - Qi, Ruogu
AU - Viswanath, Dixita I.
AU - Liu, Xuewu
AU - Chua, Corrine Ying Xuan
AU - Grattoni, Alessandro
N1 - Funding Information:
Funding: The support was provided by the Houston Methodist Research Institute and NIH-NIGMS R01GM127558 (A.G.).
Publisher Copyright:
© 2021 Elsevier Inc.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - Hypertension is a chronic condition that requires lifelong therapeutic management. Strict adherence to drug administration timing improves efficacy, while poor adherence leads to safety concerns. In light of these challenges, we present a nanofluidic technology that enables long-acting drug delivery with tunable timing of drug administration using buried gate electrodes in nanochannels. We developed a poly(ethylene glycol) methyl ether-block-poly(ε-caprolactone) (PEG-PCL)-based micellar formulation of amlodipine besylate, a calcium channel blocker for hypertension treatment. The electrostatically charged PEG-PCL micellar formulation enhanced drug solubility and rendered amlodipine responsive to electrostatic release gating in nanochannels for sustained release at clinically relevant therapeutic dose. Using a low-power (<3 VDC) gating potential, we demonstrated tunable release of amlodipine-loaded micelles. Additionally, we showed that the released drug maintained biological activity via calcium ion blockade in vitro. This study represents a proof of concept for the potential applicability of our strategy for chronotherapeutic management of hypertension.
AB - Hypertension is a chronic condition that requires lifelong therapeutic management. Strict adherence to drug administration timing improves efficacy, while poor adherence leads to safety concerns. In light of these challenges, we present a nanofluidic technology that enables long-acting drug delivery with tunable timing of drug administration using buried gate electrodes in nanochannels. We developed a poly(ethylene glycol) methyl ether-block-poly(ε-caprolactone) (PEG-PCL)-based micellar formulation of amlodipine besylate, a calcium channel blocker for hypertension treatment. The electrostatically charged PEG-PCL micellar formulation enhanced drug solubility and rendered amlodipine responsive to electrostatic release gating in nanochannels for sustained release at clinically relevant therapeutic dose. Using a low-power (<3 VDC) gating potential, we demonstrated tunable release of amlodipine-loaded micelles. Additionally, we showed that the released drug maintained biological activity via calcium ion blockade in vitro. This study represents a proof of concept for the potential applicability of our strategy for chronotherapeutic management of hypertension.
KW - Amlodipine
KW - Controlled release
KW - Drug delivery
KW - Hypertension
KW - Micelle encapsulation
UR - http://www.scopus.com/inward/record.url?scp=85110600909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110600909&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2021.102417
DO - 10.1016/j.nano.2021.102417
M3 - Article
C2 - 34171469
VL - 37
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
SN - 1549-9634
M1 - 102417
ER -